サクサク読めて、アプリ限定の機能も多数!
トップへ戻る
デスク環境を整える
www.pfizer.com
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19In the overall study population through Day 28, no deaths were reported in pa
First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strainIn trial with more than 10,000 participants 16 years of age and older, COVID-19 booster was found to have a favorable safety profileCompanies plan to submit these data to FDA, EMA and other regulatory agenci
Results are the first from a pivotal trial of any COVID-19 vaccine in children under 12 years of ageIn participants 5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responsesCompanies plan to submit these data to the FDA, EMA and other regulatory agencies around the world as soon as possibleResults in children under 5 years of age are expected as s
Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second doseVaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective in preventing severe disease as defined
Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine groupEfficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults over 65 years of age was over 94%Safety data milestone
Clinical TrialsGuide to Clinical Trials Your participation makes a difference Clinical Trials in Children Designed to improve kids' health Data and Results Sharing our Results Integrity and Transparency Building Trust Diversity Equity and Representation Plain Language Study Results Trial Result Summaries Expanded Access & Compassionate Use Possible Treatment Options Find a TrialAreas of FocusRare
Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysisAnalysis evaluated 94 confirmed cases of COVID-19 in trial participants Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional
このページを最初にブックマークしてみませんか?
『Pfizer: One of the world's premier biopharmaceutical companies』の新着エントリーを見る
j次のブックマーク
k前のブックマーク
lあとで読む
eコメント一覧を開く
oページを開く